Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Hong-Hwa Chen, William T. Chen, +12 authors Elise Chia-Hui Tan
Published 2014 in Quality of Life Research

Abstract

The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients. We conducted a prospective, open-label, observational, multicenter study from July 2008 to… (More)

DOI: 10.1007/s11136-014-0773-x

References

Sort by:

Showing 1-10 of 35 references

S. Lopatriello, C. Negrini, D. Amoroso, S. Donati, O. Alabiso, A Fornasiero
Value in Health,
2008

Capecitabine as adjuvant treatment for stage III colon cancer.

Chris Twelves, Alfred Wong, +23 authors Werner Scheithauer
The New England journal of medicine
2005

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Rachel Midgley, David J Kerr
Nature Clinical Practice Oncology
2005

Incidence and patterns of recurrence following curative resection for colorectal carcinoma.

D I Obrand, P H Gordon
Diseases of the colon and rectum
1997

Twelves, C. J. . Xeloda in adjuvant colon cancer therapy trial
Clinical Colorectal Cancer, 6(4), 278–287. Qual…
2015

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Tzu-Chi Hsu, Hong-Hwa Chen, +7 authors Li-Tzong Chen
Value in health : the journal of the…
2011

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

Lionel Uwer, Christine Rotonda, +8 authors Thierry Conroy
Health and quality of life outcomes
2011

Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.

Edward Chu, Kathy L Schulman, Edward F McKenna, Thomas Cartwright
Clinical colorectal cancer
2010

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

T Conroy, M Hebbar, +8 authors J Y Douillard
British Journal of Cancer
2010

Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.

Edward Chu, Nianwen Shi, Wenhui Wei, Johanna C Bendell, Thomas Cartwright
Oncology
2009

Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Abstract

Topics

7 Figures and Tables

Cited By

References

Metastatic colorectal cancer: medical costs of first line infusional 5-fluorouracil or oral capecitabine in Italian patients

Capecitabine as adjuvant treatment for stage III colon cancer.

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Incidence and patterns of recurrence following curative resection for colorectal carcinoma.

Overview of efficacy, safety, and costeffectiveness

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.

Slides referencing similar topics

Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Abstract

Topics

7 Figures and Tables

Cited By

References

Metastatic colorectal cancer: medical costs of first line infusional 5-fluorouracil or oral capecitabine in Italian patients

Capecitabine as adjuvant treatment for stage III colon cancer.

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Incidence and patterns of recurrence following curative resection for colorectal carcinoma.

Overview of efficacy, safety, and costeffectiveness

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.

Similar Papers

Slides referencing similar topics